BeOne Medicines Ltd. (ONC), a global oncology company, unveiled new clinical data on sonrotoclax, its next-generation investigational BCL2 inhibitor. The results demonstrate meaningful clinical benefit both as monotherapy and in combination across B-cell malignancies.
The data appeared in five presentations at the 67th American Society of Hematology Annual Meeting & Exposition in Orlando, Florida. The findings highlight durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma and additional studies showing deep, rapid, and sustained undetectable minimal residual disease rates with sonrotoclax-based combinations.
In treatment-naive chronic lymphocytic leukemia patients, sonrotoclax combined with BRUKINSA demonstrated rapid MRD negativity regardless of high-risk features, underscoring the foundational potential of this medicine in blood cancer treatment.
